ArticleFrontiers in endocrinology2026
A modular, mechanism-informed biomarker panel for asthenozoospermia based on integrative sperm proteomics.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Asthenozoospermia (AZS), defined by reduced sperm motility, is a major cause of male infertility. Comparative sperm proteomic studies of AZS versus normozoospermic men have reported differential protein expression; however, their biological interpretation remains fragmented and largely centered on individual proteins. Methods: We performed an integrative analysis of 16 independent human sperm proteomic datasets using a two-step recurrence-based strategy to identify robust AZS-associated molecular signatures. Differentially expressed proteins (DEPs) reported in at least two independent studies were considered recurrent and subjected to Gene Ontology, KEGG, Reactome, and Human Phenotype Ontology (HPO) enrichment analyses. The most highly recurrent DEPs within each direction of regulation (upregulated and downregulated) were further selected as core DEPs and analyzed through protein-protein interaction network analysis. Results: Among 2,459 non-redundant DEPs, 701 proteins (259 upregulated and 442 downregulated in AZS) were recurrently identified across studies, representing approximately 29% of all reported proteins. Recurrently upregulated proteins were primarily associated with proteostasis-related processes, RNA-related pathways, vesicle-mediated trafficking, and extracellular seminal plasma components, whereas recurrently downregulated proteins were linked to mitochondrial energy metabolism and flagellar structure. Protein-protein interaction network analysis of the core DEPs, integrating both upregulated and downregulated sets, revealed four conserved functional modules across sperm compartments: structural, metabolic, vesicular trafficking, and extracellular. Discussion: These findings show that molecular alterations in AZS converge at the level of functional modules rather than representing isolated protein-level dysregulation. This modular architecture defines a mechanism-informed biomarker panel that captures key processes underlying AZS, helps reconcile discrepancies among studies, and provides a framework for molecularly grounded diagnostics and future validation through multi-omics and artificial intelligence approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.